Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967204 | 0.83 | ALOX5 (0.45) | BACE1ALOX5CNR1ADORA1BRD4 | |
| SCHEMBL1970423 | 0.82 | ALOX5 (0.64) | BACE1ALOX5CREBBPADORA1ATM | |
| SCHEMBL13464238 | 0.82 | CNR1 (0.41) | BACE1ALOX5CREBBPCNR1BRD4 | |
| SCHEMBL1967015 | 0.81 | PKM (0.53) | BACE1JAK1JAK2BRD4APP | |
| SCHEMBL1967088 | 0.81 | BACE1 (0.55) | BACE1ALOX5CNR1ADORA1BRD4 | |
| SCHEMBL1965238 | 0.81 | ALOX5 (0.45) | BACE1ALOX5CNR1ADORA1 | |
| SCHEMBL1970632 | 0.80 | BACE1 (0.54) | BACE1ALOX5ADORA1BRD4 | |
| SCHEMBL1967772 | 0.79 | ALOX5 (0.43) | BACE1ALOX5CNR1ADORA1 | |
| SCHEMBL13464262 | 0.79 | ALOX5 (0.43) | BACE1ALOX5CNR1ADORA1 | |
| SCHEMBL1964933 | 0.79 | ALOX5 (0.43) | BACE1ALOX5CNR1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | claimed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | claimed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | BACE1 2906/4885ALOX5 3673/4885CREBBP 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.